4 results about "Antibody-Producing Cells" patented technology

A protein nanospheres and method to treat dysfunction from chemotherapy and immunosuppressive therapy, and a manufacture of fibrinogen-coated albumin spheres (FAS) and High-Fibrinogen Spheres (HFS) which have higher concentrations of fibrinogen molecules per sphere than FAS, and their use for medical treatments. Both kinds of nanoparticles are effective in the mitigation of the toxic effects of certain chemotherapeutic and radiological agents that are typically used in the treatment of cancer, or the treatment of autoimmune diseases, or for patients with both diseases. FAS and HFS can exert their beneficial effects via a variety of mechanisms which match the need of the body for specific cell types, including any of the subgroups of T cells and antibody producing cells, the relative concentration of each kind is vital to the balance between tumor surveillance and autoimmune disease suppression.

A method is derived for identifying high affinity monoclonal antibody heavy and light chain pairs from high throughput screens of antibody producing cell libraries such as B-cell and hybridoma libraries. Specifically, the method relates to application of reversed immunocapture and high resolution tandem mass spectrometry for the identification of heavy and light chain pairs of binding antibodies obtained from high throughput screens of antibody producing cell libraries.

Disclosed herein is a method for obtaining antibody-producing cells that express antibody molecules exhibiting high binding affinity to an antigen, comprising: contacting a population of antibody-producing cells, including cells expressing antibody molecules against an antigen on their cell surface, with a first labeled form of the antigen to enable the antigen to bind to antibody molecules on the cell surface; subsequently contacting the cells with (i) an unlabeled form of the antigen, (ii) a second labeled form of the antigen, or (iii) both the unlabeled and second labeled forms of the antigen; and collecting cells that remain bound to the first labeled form of the antigen, thereby obtaining cells that express antibody molecules with high affinity to the antigen. This method makes it possible to obtain cells expressing high-affinity antibody molecules from a pool of antibody-producing cells expressing antibody molecules with different affinities.

The present invention aims to provide a method for immortalizing antibody-producing cells and the immortalized transformed cells obtained by this method. The present invention relates to a method for manufacturing immortalized cells, which involves introducing one or more genes selected from the group consisting of the SV40T antigen gene, the Bcl-2 family gene, and the Myc family gene and the Cyclin D family gene into non-immortalized antibody-producing cells. The present invention also relates to a method for manufacturing immortalized antibody-producing cells, which involves collecting antibody-producing cells from mammals, performing primary culture, and introducing one or more genes selected from the group consisting of the SV40T antigen gene, the Bcl-2 family gene, and the Myc family gene and the Cyclin D family gene into the obtained primary antibody-producing cells to create immortalized antibody-producing cells.